Overview

Beta-glucans for Hospitalised Patients With COVID-19

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This randomised trial aims to assess the role of beta1-3 glucan supplementation in improving clinical symptoms and other outcomes amongst hospitalised patients with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Concentra Educacion e Investigación Biomédica
Collaborator:
Wohlstand Pharmaceutical